Literature DB >> 12185293

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.

M Malet-Martino1, R Martino.   

Abstract

Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro- and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines. In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation. The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented. The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185293     DOI: 10.1634/theoncologist.7-4-288

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  78 in total

1.  Antitumor activity of novel N-sulfonylpyrimidine derivatives on the growth of anaplastic mammary carcinoma in vivo.

Authors:  Marina Pavlak; Ranko Stojković; Matea Radacić-Aumiler; Jelena Kasnar-Samprec; Jure Jercić; Ksenija Vlahović; Biserka Zinić; Marko Radacić
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.553

Review 2.  Current directions in chemotherapy for colorectal cancer.

Authors:  Yasuhiro Inoue; Chikao Miki; Masato Kusunoki
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery.

Authors:  Qi-da Hu; Hui Fan; Wei-jian Lou; Qing-qing Wang; Gu-ping Tang
Journal:  J Zhejiang Univ Sci B       Date:  2011-09       Impact factor: 3.066

4.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 5.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

Review 6.  How multi-organ microdevices can help foster drug development.

Authors:  Mandy B Esch; Alec S T Smith; Jean-Matthieu Prot; Carlota Oleaga; James J Hickman; Michael L Shuler
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

7.  Variability in the anti-tumor effect of tegafur-uracil depending on histologic types of lung cancer.

Authors:  Bo-Ram Lee; Jin-Yeong Yu; Seong-Hoon Yoon; Hee-Jung Ban; Yong-Soo Kwon; In-Jae Oh; Kyu-Sik Kim; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

8.  A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

Authors:  Sun Young Kim; Yong Sang Hong; Byung Chang Kim; Ji Won Park; Hyo Seong Choi; Seung-Yong Jeong; Dae Yong Kim; Chang Won Hong; Dae Kyung Sohn; Kyung Hae Jung
Journal:  Invest New Drugs       Date:  2008-09-25       Impact factor: 3.850

9.  Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice.

Authors:  Mamoru Nukatsuka; Hitoshi Saito; Fumio Nakagawa; Hiroaki Tsujimoto; Kazuki Sakamoto; Sayaka Tsukioka; Junji Uchida; Mamoru Kiniwa; Takashi Kobunai; Teiji Takechi
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

10.  Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.

Authors:  W Koizumi; N Boku; K Yamaguchi; Y Miyata; A Sawaki; T Kato; Y Toh; I Hyodo; T Nishina; T Furuhata; K Miyashita; Y Okada
Journal:  Ann Oncol       Date:  2009-10-14       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.